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hight dose gradient regions. This same was made in 7 clinical plans. 
Also, 2 plans in validation and 8 plans in clinical practice were 
recalculated in an alternative phantom due to geometric 
uncertainties. 
Conclusions: The agreement between measurements and Diamond 
may be interpreted as an absence of systematic errors. In the same 
way the comparison between Eclipse and Diamond produced very 
similar results. One year experience shows results very close to those 
obtained in validation. This agreement led us to consider Diamond a 
valuable tool for QA in VMAT plans. 
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Purpose/Objective: The MONACO treatment planning system (TPS) 
(Elekta), which employs an X-ray Voxel Monte Carlo (XVMC) algorithm 
is currently used in radiation therapy. The XVMC calculation is reliable 
for determining absorbed dose of X-ray in the heterogeneous region. 
Therefore, the MONACO TPS could be useful for an independent dose 
calculation in a high precision treatment. So, we developed a 
conversion program of a beam format in Pinnacle3 TPS to that in 
MONACO TPS. In this study, we present the dose comparison between 
them for prostate, lung, head and neck, and esophagus cancer 
patients treated by Volumetric Modulated Arc Therapy (VMAT). 
Materials and Methods: Eight patients (prostate; 5, lung; 1, head and 
neck; 1, esophagus; 1) treated by single-arc VMAT were selected for 
this study. The treatment plan was created by SmartArc (Pinnacle3, 
Philips) with the superposition/convolution algorithm. The calculation 
voxel space was 2 mm. Then, the beams from SmartArc were exported 
into the MONACO TPS, where the dose distribution was recalculated 
with 3 mm of the calculation voxel space and 3% of the variance. The 
comparison was performed by analysing the dose volume histogram 
(DVH) and the dose difference. 
Results: The differences in PTV D50 (covering 50% of the planning 
target volume) were about 0.6%, 1.4%, 1.2%, and 1.3% for prostate, 
lung, head and neck, and esophagus cancer cases, respectively. 
Although the dose difference tended to be relatively large for the 
organs at risk, the serious discrepancy was not observed. Figure shows 




Conclusions: It was feasible to use a commercially available TPS 
based on a Monte Carlo code as an independent dose calculation for 
VMAT. In this study, the dose comparison was performed in the 
various parts, so that no remarkable difference between the 
superposition/convolution calculation and XVMC calculation was 
found. 
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Purpose/Objective: The purpose of this study is to evaluate the 
differences between dose distributions calculated with Pencil Beam 
(PB) and X-ray Voxel Monte Carlo (XVMC) algorithm. Calculations 
performed with the PB algorithm is reasonably accurate for tumors 
located in homogeneous regions but PB tends to overestimate the 
dose distribution where large inhomogeneities exist. Moreover, for 
intensity modulated radiation therapy (IMRT) dose calculation can be 
more complex due to the combined effect of many small fields and 
the presence of steep fluence gradients.  
Materials and Methods: Treatment plans were developed for 45 lung 
cancer patients with iPlan, Brainlab. For each patient an IMRT or 
HybridArc plan calculated with PB algorithm was developed to give 40 
Gy at 8 Gy/ fraction with five no coplanar 6 MV beams or 3-4 dynamic 
conformal arcs with 3-5 IMRT beams distributed per arc (for HybridArc 
plans). Each optimized plan was recalculated with the XVMC algorithm 
with the same monitor units (MU). Secondly XVMC plans were 
renormalized to give the prescribed dose to the tumour and 
differences between MU to be delivered were evaluated. For four 
patients, evaluations have been performed also in the case of CT 
scans acquired under deep- breath condition. Differences in dose 
distributions were evaluated in terms of dose volume histograms 
(DVHs). To estimate the impact of the observed differences on 
treatment outcome, tumour control probability (TCP) and normal 
tissue complication probability (NTCP) were calculated. Thirdly a 
typical IMRT treatment plan was performed on CT data of an 
anthropomorphic phantom and calculated doses on significant planes 
were compared to measurements performed with GAFCHROMICTM 
EBT3.  
Results: Differences between mean tumour dose calculated with PB 
and XVMC were about 10±4 %, even larger in deep-breathing 
conditions, while differences between doses to significant volumes for 
organs at risk (OARs) were generally lower. After normalization, MUs 
for XVCM were always higher than for PB though not significantly (p = 
0.0531). TCP ranged from (99.9 ± 0.1) % to (87.1 ± 9.7) % for PB 
calculated plans respect to XVMC while NTCP on OARs did not vary 
significantly. In the deep-breathing condition TCP ranged from (99.9 ± 
0.3) % to (66.9 ± 17.2) % for PB and XVMC, respectively. The 
dosimetric evaluation confirmed the better accuracy in calculation of 
XVMC, the agreement in terms of absolute gamma function (gamma<1, 
3 %, 3mm) was about 94 % for XVMC and lowered down to 67 % for PB. 
Conclusions: Results showed that PB calculation leads to overestimate 
the dose with respect to the XVMC for the points inside the tumour, 
for each case the major discrepancies were observed along the 
boundary between tissue and air. The increase in MU due to the 
renormalization of the plans to have comparable mean doses to the 
tumour was not significant and the calculated NTCP values for OARs 
were far below the allowed tolerable values. 
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Purpose/Objective: Out-of-field dose to multiple organs has been 
evaluated for secondary cancer risk assessment using Monte Carlo 
calculation for breast preserving radiotherapy. Dose contributions 
from internal body scattering and linac head scattering have been 
separately calculated and compared. 
Materials and Methods: Monte Carlo codes, EGSnrc and 
DOSXYZnrc,were employed to evaluate out-of-field dose to various 
organs of breast cancer patients who received breast conserving 
radiotherapy. The out-of-field dose results from linac head scattering 
as well as internal body scattering ofdirect x-ray beams. These two 
scattering contributions were separately calculated by the Monte 
Carlo codes with a photon energy of 6 MV and a dosegrid size of 4 x 4 
x 6 mm3. Doses on the patient body surface and in various organs were 
calculated, whereas patient doses were also measured using glass rod 
dosimeters, GD-301 (Chiyoda Technol, Japan), in various body surface 
locations. To reduce statistical uncertainty, the number of photons 
was increased to 1 x 1010. To further verify the accuracy of the Monte 
Carlo calculation for the patient, surface and internal doses of RAND 
phantom were also calculated and compared to measured results 
using the glass rod dosimeter.  
 
